摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-(2-Methoxyphenoxy)ethyl]pyrrolidine

中文名称
——
中文别名
——
英文名称
1-[2-(2-Methoxyphenoxy)ethyl]pyrrolidine
英文别名
——
1-[2-(2-Methoxyphenoxy)ethyl]pyrrolidine化学式
CAS
——
化学式
C13H19NO2
mdl
——
分子量
221.29
InChiKey
WRVYQWCFAABEKV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    16
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    21.7
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS
    申请人:Vu Chi B
    公开号:US20110124637A1
    公开(公告)日:2011-05-26
    Provided herein are sirtuin-modulating compounds of formula (II). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders relating to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    本文提供的是公式(II)的sirtuin调节化合物。这些sirtuin调节化合物可用于延长细胞寿命,并治疗和/或预防各种疾病和疾患,包括与衰老或压力有关的疾病或疾患、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红,以及需要增加线粒体活性的疾病或疾患。还提供了包含sirtuin调节化合物与另一种治疗剂的组合物。
  • [EN] METHODS OF TREATING THALASSEMIA<br/>[FR] PROCÉDÉS DE TRAITEMENT DE LA THALASSÉMIE
    申请人:TARGEGEN INC
    公开号:WO2010017122A2
    公开(公告)日:2010-02-11
    Provided herein are method of treating, ameliorating, or delaying at least one symptom of a genetic blood disorder, e.g. sickle cell disorder or thalassemia, in a patient in need thereof, comprising administering a therapeutically effective amount of a Jak2 inhibitor. Also provided in part is a method of reducing an enlarged spleen in a patient suffering from thalassemia, comprising administering a therapeutically effective amount of a Jak2 inhibitor.
查看更多